Skip to main content
padlock icon - secure page this page is secure

Mechanism by which Regulatory Rheumatoid Factor Prevents Experimental Autoimmune Encephalomyelitis

Buy Article:

$68.00 + tax (Refund Policy)

Background: One mechanism that underlies protection from autoimmunity and avoidance of uncontrolled inflammation is the controlled contraction of lymphocyte expansion during the immune response. We identified regulatory rheumatoid factor (regRF), the production of which is associated with resistance to and remission of experimental autoimmune diseases. RegRF is anti-idiotypic antibodies to lymphocyte receptors against autoimmune disease-inducing antigens; at the same time, it is specific to epitopes in the hinge Fc fragments of IgG.

Objective: The aim of this study is to test the hypothesis that regRF prevents autoimmunity by limiting the expansion of lymphocytes.

Methods: To test this hypothesis, we used a model of experimental autoimmune encephalitis.

Results: We found that in the lymph nodes that drain the injection site in rats producing regRF in response to immunization with myelin basic protein (MBP) the proportion of CD4+lymphocytes was lower than in rats in which MBP-immunization did not induce higher regRF levels. RegRF-containing plasma obtained from MBP-immunized rats induces complement-dependent killing of MBP-activated lymphocytes. Activated MBP-specific lymphocytes are not sensitive to the regRF-containing plasma of intact rats.

Conclusion: The regRF produced during the immune response is a specific control factor for the expansion of antigen-activated CD4+lymphocytes.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: CD4+CD95+ lymphocytes; Experimental autoimmune encephalomyelitis; activated CD4+ lymphocytes; complement-dependent lysis; controlled contraction of lymphocyte expansion; regulatory rheumatoid factor

Document Type: Research Article

Publication date: November 1, 2018

More about this publication?
  • This journal is devoted to timely reviews of experimental and clinical studies in the field of endocrine, metabolic, and immune disorders. Specific emphasis is placed on humoral and cellular targets for natural, synthetic, and genetically engineered drugs that enhance or impair endocrine, metabolic, and immune parameters and functions. Topics related to the neuroendocrine-immune axis are given special emphasis in view of the growing interest in stress-related, inflammatory, autoimmune, and degenerative disorders.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more